| |
Figure 7 (A–F) Immunolabeling with various neuroepithelial cell markers indicates that the
neuroepithelium was not obviously affected by treatment with 250 and 500 M CGP54626. (A–B)
Immunocytochemistry with an antibody against islet-1 shows ventrally located cells in both control
(0.5% DMSO)- (A) and 500 M CGP54626- (B) treated brains. (C–D) Zn-12, a general neural
marker, exhibits comparable labeling in control (1% DMSO)- (C) and 250 M CGP54626- (D)
treated brains. (E) Unexposed (UnEx) and exposed (Ex) sides of a 250 M CGP54626-treated brain
show comparable immunolabeling with an antibody against -tubulin. (F) GABA immunoreactivity
is unaffected by treatment with 500 M CGP54626. Bar in F is 100 m. (G) Mean normalized optic tract
length in control and GABA-B receptor antagonist treated brains. For each CGP54626
concentration, control brains were exposed to equivalent levels of the DMSO carrier. CGP54626
caused a dose-dependent shortening of the optic projection, whereas phaclofen had no obvious effect
on the optic projection. *p .05, **p .01 (unpaired, two-tailed Student t test). Numbers in
brackets are the number of embryos from three to five separate experiments. |
